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ABSTRACT: 
Aims: Recent studies have associated obesity with subclinical diastolic dysfunction (DD). However, few data are 
available on the relative contribution of adiposity distribution on changes in myocardial structure and function. 
Our aim was to evaluate the role of abdominal fat distribution (visceral versus subcutaneous) and epicardial fat 
volume on diastolic function in patients after acute myocardial infarction (AMI). 
Methods and Results: One month after AMI, 225 consecutive patients were prospectively enrolled and underwent 
detailed transthoracic echocardiography (mitral inflow analysis, pulmonary vein flow, tissue Doppler evaluation), 
computed tomography (quantification of epicardial fat volume and total, subcutaneous and visceral abdominal fat) 
and anthropometric evaluation with bioimpedance analysis. 
We found a significant association between DD parameters, such as E’ velocity, with body mass index (r= -
0.16;p=0.02), fat mass percentage (r= -0.25;p=0.02) and waist perimeter (r= -0.27;p<0.001). E’ velocity and E/E’ 
ratio were significantly correlated with total and visceral abdominal fat area (r=-0.27, p<0.001 and r=0.21, p<0.01 
respectively), but not with subcutaneous fat. 
After multivariate regression analysis, epicardial adipose tissue (EAT) showed a significant association with 
lateral E’ velocity (p<0.01) and increased E/E’ mean ratio (p<0.01). Patients with diastolic dysfunction had higher 
EAT volumes (116.7±67.9 ml versus 93.0±52.3 ml; p=0.01) and there was a progressive increase in EAT 
according to increasing severity DD grades (p for trend =0.001).  
None of the adiposity parameters correlated with systolic function parameters. 
Conclusions: Obesity, mainly central and visceral fat, was significantly correlated with DD parameters. Increased 
epicardial fat volume was also an independently correlated with impaired diastolic function. 
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1. INTRODUCTION 
Diastolic dysfunction (DD) is characterized by an abnormality of the left ventricle to relax and/or to fill with an 
adequate volume of blood, at normal diastolic filling pressures (1, 2). This disorder is common in the community 
(3) and is recognized as an important predictor of heart failure (4) and long-term mortality (3, 5). After acute 
myocardial infarction, the importance of diastolic function assessment has been frequently overlooked. However, 
in these patients DD is a major determinant of adverse clinical outcome (6) and decreased functional capacity. 
Left ventricle (LV) diastolic dysfunction is mainly associated with age, hypertension, coronary artery disease 
(CAD) and/or diabetes (7). Some very recent studies have also demonstrated that obesity is related with subclinical 
DD (8, 9). There are several pathophysiological pathways that can explain this association, involving both indirect 
and direct mechanisms (10). First, obesity is associated with several other comorbidities, such as hypertension, 
diabetes mellitus and CAD that can impact diastolic function (11). On the other hand, obesity can directly affect 
cardiac structure and function, causing chronic volume overload, hyperdynamic circulation and increased 
peripheral resistance, which induces increased LV preload and afterload (9, 12). Furthermore, it is also recognized 
that the adipose tissue, especially visceral fat, can induce a pro-inflammatory state and secrete several adipokines 
which can directly influence myocardial structure and function (13). 
Only a few previous studies have assessed the relative importance of visceral versus subcutaneous adiposity as 
determinants of DD. The few data available suggest that visceral fat, the most metabolically active fat depot, can 
be a more important determinant of DD (14). Moreover, the heart itself is covered by fat, the epicardial adipose 
tissue (EAT) (15). Because EAT secretes proinflammatory, proatherogenic and protrombotic adypokines (16, 17) 
and there is no physical barrier separating it from the adjacent myocardium and coronary arteries, EAT can have a 
local metabolic role by a paracrine effect (18). In fact, several studies have demonstrated that EAT is associated 
with the development and progression coronary artery disease (19-23), independently of other cardiovascular risk 
factors or other fat deposits, and possibly with changes in myocardial structure and function (24-27). 
In this study our aims were to assess: 1) the role of total versus central adiposity parameters as determinants of 
diastolic dysfunction; 2) the relative importance of total, subcutaneous and visceral abdominal fat mass in this 
association; 3) the influence of epicardial adipose tissue on myocardial systolic and diastolic function. 
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2. METHODS 
2.1. Patient population and study protocol 
The present study included 225 consecutive patients referred to a cardiac rehabilitation program, one month after 
an acute myocardial infarction. Exclusion criteria were age above 75 years, inability to exercise, severe valvular 
heart disease, moderate or severe chronic lung disease, atrial fibrillation or exercise induced myocardial ischaemia.  
All patients were prospectively enrolled and were submitted on the same day to clinical evaluation (performed by 
a cardiologist), anthropometric evaluation, detailed transthoracic echocardiography, computed tomography (CT) 
scan and blood sample collection.  
The investigation conforms with the principles outlined in the Declaration of Helsinki and was approved by the 
institution's ethical committee. All patients gave their written informed consent. 
 
2.2. Anthropometric evaluation 
Measurements included height, weight and waist circumference (WC). Body mass index (BMI) was calculated for 
each subject. WC was measured at the midpoint between the iliac crest and the lower rib margins, measured in the 
midaxillary line. According to World Health Organization criteria, overweight was defined as body mass index 
(BMI) between 25 and 30 Kg/m2 and obesity as BMI>30 kg/m2. Abdominal obesity was defined as WC>102 cm 
in men and >88 cm in women.  
Body composition assessment was performed by bioelectrical impedance analysis (Tanita Column Adult 
Weighing Scale®) to determine body fat percentage (%). 
 
2.3. Echocardiography assessment protocol 
All echocardiography studies were acquired by a single experienced cardiologist using an ultrasound system (iE33, 
Philips Medical Systems, Best, The Netherlands) equipped with a S5-1 transducer. Images were digitally stored 
for posterior offline analysis.  
Cardiac chambers dimensions; volumes and left ventricular mass were measured according to current 
recommendations (28). Mitral inflow velocities were assessed using pulsed-wave (PW) Doppler in the apical four-
chamber view, with a 3 mm sample placed between the tips of the mitral leaflets; velocities were recorded at end-
expiration and averaged over three consecutive cardiac cycles. PW tissue-Doppler velocities were acquired at end 
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expiration, in the apical four-chamber view, with the sample positioned at the septal and lateral mitral annulus. PW 
Doppler velocities at the upper right pulmonary vein were also recorded. For all parameters the average of three 
consecutive heartbeats was recorded. 
Diastolic function was assessed according to the recent consensus guidelines on diastolic function evaluation (29) 
by determining peak early (E) and late (A) diastolic mitral inflow velocities, deceleration time of early left 
ventricular filling (DT), the E/A ratio, the septal, lateral and average myocardial annular tissue velocity (E’sep, 
E’lat, E’mean, respectively), the E/E’ ratio (also the septal, lateral and mean E/E’), pulmonary vein flow analysis 
(to calculate the Ard-Ad difference: the time difference between the duration of the atrial reversal wave of the 
pulmonary flow – Ard – and the mitral A-wave duration) and isovolumic relaxation time (IVRT). Using the recent 
EAE/ESC guidelines on diastolic function evaluation (29), patients were categorized in diastolic dysfunction (DD) 
grades – normal, grade I (mild DD), grade II (moderate DD) and grade III (severe DD), by two independent 
cardiologists who were blinded for the study data. In case of discordance, each case was discussed individually, 
and if doubt persisted no grade was endorsed, which happened in 20 patients (8.9%). 
 
2.4. CT scan protocol: Abdominal and Epicardial Fat assessment 
Multidetector CT scans were performed in all patients using a 64-slice CT scanner (Somatom Sensation 64, 
Siemens Medical Solutions, Forchheim, Germany) with two different acquisitions: one for abdominal fat 
quantification and the other for epicardial adipose tissue quantiﬁcation. 
To assess abdominal fat, a single-slice abdominal CT scan was performed between L4 and L5, according to the 
method described by Borkan et al (30). The scan parameters were 120 kV and 216 mAs with 5 mm thickness. This 
resulted in an estimated radiation exposure of 0.06 mSv. On the scan obtained, a cursor pointer was used to trace 
the abdominal visceral fat area, and the data were processed using a histogram-based statistical program according 
to the previously described method (31, 32). One expert, unaware of the patient’s details, measured abdominal fat 
distribution. Fat tissue was defined in the range between -150 and -50 Hounsﬁeld units (HU). Total abdominal fat 
area was measured and subcutaneous fat area was obtained by subtracting abdominal visceral fat from the total 
abdominal fat area.  
An experienced radiographer, blinded for the purpose of the study and the patient’s anthropometric data, 
quantified epicardial fat volume. A cursor pointer was used to manually trace the pericardial contour using 1-mm-
	   6	  
thick reconstructed axial slices. Pericardium contour was traced for every 10 mm, starting from the lower visible 
level of pulmonary artery bifurcation until the top level of the pulmonary valve, for every 20 mm from there until 
the first slice where the diaphragm becomes visible and, again, for every 10mm from this point until the last slice 
where pericardium is still visible (31), as illustrated in figure A.1. The pericardium contour was extrapolated by 
the software (Syngo Volume, Siemens Medical Solutions) for the non-traced slices and rechecked by the operator. 
Within these anatomical limits, EAT was identified using the adipose tissue attenuation references (from -150 to -
50 HU) and a final EAT volume resulted from the sum of all slices of fat values. 
 
2.5. Statistical analysis 
Statistical analysis was performed with SPSS program version 20. All continuous variables are shown as a mean ± 
SD for normally distributed variables or as a median and interquartile range for non-normally distributed. 
Categorical variables are expressed as a number (n) and percentage (%). Statistical significance was defined as 
p<0.05. 
Spearman correlation coefficient (r) was analysed to access the correlations between cardiac function and structure 
echocardiographic parameters and adiposity parameters obtained by anthropometry and CT scan. To compare 
median values of several adiposity parameters according to diastolic function grades, non-parametric tests were 
used (Mann–Whitney and Kruskal-Wallis, accordingly). 
Linear regression analysis was performed for univariate and multivariate analysis of fat distribution variables that 
predict worse diastolic function. Multivariate analysis was performed accordingly with adjustment for age, 
hypertension, sex and several fat depots.  
 
3. RESULTS 
The clinical, anthropometric and analytical characteristics of the study population are summarized in table A.1. 
Most patients were men (84%), with a mean age of 55.1±10.9 years, 47.6% were overweight and 20.9% were 
obese. The mean ejection fraction was 53.6±9.3% and the majority of patients (64.4%)) had some degree of 
diastolic dysfunction: 27.8% had grade 1 DD, 28.3% had grade 2 DD, 4.4% had severe DD and 35.6% had normal 
diastolic function. 
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3.1. Diastolic function and adiposity parameters 
As shown in table A.2, there was a significant correlation between BMI and decreased early diastolic velocity (E’ 
lateral) and increased LV filling pressures (E/E’ mean). Fat mass percentage, assessed by bioelectric impedance 
analysis, was also inversely correlated with E’ septal velocity (r= -0.26, p<0.01), E’ lateral velocity (r= -0.25; 
p<0.01) and E/E’ mean ratio (r= 0.28; p<0.01). On the other hand, as shown in table A.4, there was a significant 
increase in fat mass percentage, according to the classification in diastolic dysfunction grades (p for trend < 0.01). 
After multivariate analysis, with adjustment for age, sex and hypertension history, the association between fat 
mass percentage and early diastolic velocities (E’ septal and lateral) remained significant, as shown in table A.3.   
The correlation between diastolic function and adiposity parameters is better with central obesity (assessed by 
waist-perimeter/height) than with total fat parameters, such as BMI (table A.2). Also, the association between 
waist-perimeter/height and E’ lateral velocity is independent of BMI or fat mass percentage (p<0.01). As shown in 
table A.3, after multivariate adjustment, for each unit increase in waist-perimeter/height there is a decrease of -
0.09 (95%CI: -0.15 to -0.03; p<0.01) in E’ lateral velocity (see table A.3). 
3.2. Association between diastolic function and abdominal fat mass (total, subcutaneous and visceral fat) 
When analysing the association between diastolic function and abdominal fat distribution assessed by CT scan, 
increased total abdominal fat mass significantly correlated with decreased E’ velocities and increased E/E’ ratios 
(as shown in table A.2 and in figure A.1). Patients with diastolic dysfunction have increased total abdominal fat 
mass, as shown in table A.4.  
There was a significant correlation between E’ lateral and E’ septal velocities with visceral abdominal fat mass, 
but not with subcutaneous fat, as shown in table A.2: r= -0.27, p<0.01, between E’ lateral and visceral fat mass 
versus r= -0.09, p=0.20, between E’ lateral and subcutaneous fat (see also figure A.1). According to the 
classification in diastolic dysfunction grades, we saw an increase in visceral abdominal fat (p for trend = 0.01) but 
not in subcutaneous abdominal fat mass (p for trend = 0.13) with worse diastolic function. 
3.3. Epicardial fat volume and diastolic dysfunction 
Epicardial fat volume was significantly correlated with all echocardiographic diastolic dysfunction parameters, 
namely with reduced lateral and septal E’ velocities and with higher septal, lateral and mean E/E’ ratios (table A.2 
and figure A.3). Also, across diastolic dysfunction grades there is a progressive increase in epicardial fat volume 
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(p for trend, 0.001), as shown in figure A.4.  Patients with any degree of diastolic dysfunction have significantly 
higher epicardial fat volumes (116.7±67.9 ml in patients with DD versus 93.0±52.3 ml in patients with normal 
diastolic function). The association between epicardial fat volume and E’ lateral velocity is independent of other 
adiposity parameters (p<0.01 after adjustment for total fat mass percentage, p<0.01 after adjustment for total 
abdominal fat and p=0.03 after adjustment for visceral fat).   
After multivariate regression analysis with adjustment for age, sex and hypertension, increased epicardial fat is 
associated with a decreased lateral E’ velocity (p<0.01), septal E’ velocity (p=0.02) and an increased E/E’ mean 
ratio (p<0.01), as shown in table A.3.  
 
3.4. Association of adiposity parameters with other cardiac structural and functional changes 
No significant association was found between total body fat parameters such as BMI, waist-perimeter/height and 
fat mass percentage with systolic function, namely with ejection fraction or with systolic mitral annulus velocities 
determined by tissue Doppler (S’ septal and S’ lateral). Also, neither abdominal fat mass (either total fat, 
subcutaneous or visceral fat) neither epicardial fat volume correlate with any systolic function parameter (figure 
A.3). 
 
4. DISCUSSION 
In this study, we analysed the association of several adiposity parameters with diastolic function and observed that: 
1) overall, there is a significant association between increased total adiposity and impaired diastolic function; 2) 
this association seems to be stronger with central/visceral adiposity than with subcutaneous or total fat parameters; 
and 3) the association of epicardial fat volume with diastolic dysfunction is independent of other cardiovascular 
risk factors (namely ageing and hypertension), gender and other adiposity parameters. On the contrary, we did not 
find any association between increased adiposity and systolic function. 
The current study is, to the best of our knowledge, the first analysing in detail this recently discovered association 
between several adiposity parameters, including epicardial fat, and diastolic dysfunction. Fat distribution was 
analysed with classical anthropometry parameters, but also using CT scan data for determination of total, visceral 
and subcutaneous abdominal fat mass and epicardial fat volume. CT scan is considered the best method to assess 
epicardial fat (33). On the other hand, diastolic function was assessed according to the most recent consensus 
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document for the evaluation of left ventricle diastolic function (29) which recommends the analysis of tissue 
Doppler derived parameters especially, early mitral annulus velocity (E’ wave) that is a relatively preload-
independent index of LV relaxation and the ratio between peak early diastolic mitral inflow velocity and 
myocardial velocity (E/E’) that can be used to estimate LV filling pressures (29). As recommended, for the 
categorization in DD grades the integrated diagnostic algorithm was also used which includes the analysis of 
mitral inflow pattern, tissue Doppler velocities, pulmonary vein flow and left atrium volume(29). 
 
4.1. The relation of diastolic dysfunction with total and central adiposity 
Our results are in accordance with very recent studies that have shown an association between increased adiposity 
and diastolic dysfunction (8, 34). In a general population sample, Russo et al. (34) found an association between 
increased BMI and reduced early diastolic mitral annulus velocity (E’), increased filling pressures (E/E’) and the 
presence of diastolic dysfunction. However, it is known that BMI is not a good marker of fat accumulation 
because it is influenced by several other factors (35). In our study, we have shown that worse diastolic function is 
associated not only with increased BMI, but also with increased fat mass percentage (assessed by bioelectric 
impedance), which reinforces the association between fat accumulation and diastolic dysfunction. 
This association between obesity and diastolic function was independent of traditional cardiovascular risk factors, 
suggesting that other pathophysiological mechanisms are responsible for this association. Adipose tissue can 
modulate the cardiovascular system by several metabolic and neuroendocrine pathways, which include 
abnormalities in sodium balance, neuroendocrine activation of the renin-angiotensin-aldosterone axis and of the 
sympathetic system (36), secretion of adipokines that can directly influence myocardial structure and function 
(13), low grade-inflammation and increased myocardial oxidative stress (37).  
It is also known that visceral adipose tissue is inherently different from subcutaneous fat in several processes 
involving lipolysis and lipogenesis. Visceral fat is the metabolically most active organ, secreting several 
adipokines and contributing to a systemic pro-inflammatory state that can affect cardiovascular system (13). On 
the other hand, inflammation has been linked with diastolic dysfunction in patients with hypertension (38) and 
coronary artery disease (39) and experimental studies have shown that inhibition of inflammatory pathways can 
prevent diastolic dysfunction (40). Integrating these recent data, Paulus et al. (41) proposed a novel paradigm for 
the development of heart failure with preserved ejection fraction which identifies a systemic pro-inflammatory 
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state (induced by obesity and other comorbidities) as a cause of reduced nitric oxide availability and decreased 
protein kinase G activity, therefore inducing stiffer cardiomyocytes and interstitial fibrosis deposition and, as a 
consequence, diastolic dysfunction. 
In our study, diastolic dysfunction correlated more strongly with central and visceral adiposity parameters than 
with measures of total and subcutaneous obesity. A similar finding showing an association between waist-
perimeter and diastolic dysfunction, independent of BMI, has also been recently demonstrated in the general 
population (8). Another study from the Baltimore Longitudinal Study of Aging, in which abdominal visceral and 
subcutaneous fat was measured using CT scan, also showed that although both visceral and subcutaneous fat were 
associated with LV diastolic dysfunction, only visceral fat was significantly associated with LV diastolic 
dysfunction when both were included in the same model (14). Our data are also in accordance with these findings. 
 
4.2. The association between epicardial fat and diastolic function 
In this study we have shown that increased epicardial fat volume was significantly associated with worse diastolic 
function. This association was independent of other diastolic dysfunction determinants, such as ageing, sex and 
hypertension history. A similar finding has been recently reported showing an association between epicardial fat 
thickness (determined by echocardiography), but not visceral adipose tissue, with subclinical diastolic in peritoneal 
dialysed patients (25).  
Epicardial fat has special properties that distinguish it from other visceral fat components. It directly covers the 
heart and the coronary arteries without any mechanical barrier to the cardiomyocytes and vessels and also sharing 
the same blood supply (42). Therefore, because EAT is an important source of several pro-inflammatory and pro-
atherogenic cytokines, EAT can have a direct effect on coronary atherosclerosis and/or cardiac structure and 
function (18, 43). Recently, several studies have recognized increased EAT as an independent determinant of the 
development and progression of coronary artery disease (CAD) (22, 31, 44), presence of myocardial perfusion 
abnormalities (45) and vulnerable coronary atherosclerotic plaques (21). EAT is a stronger determinant of CAD 
than visceral adiposity located in other body compartments (19). 
EAT can also directly influence myocardial structure and function by mechanical, systemic and paracrine 
pathways. The systemic effects of obesity on cardiac function were described above. Our data are in accordance 
with other studies (25-27) suggesting a direct influence of EAT on diastolic function, possibly mediated by local 
	   11	  
mechanical or paracrine effects.  First, epicardial fat volume can range from 50 g to >250 g and, therefore, induce 
an outside compression of the heart which can pose a mechanical limitation to cardiac expansion, further 
deteriorating DD (24). Local paracrine inflammatory pathways can also play an important role in this association. 
In an interesting study, using biopsies of patients undergoing elective CABG, it was shown that epicardial adipose 
tissue is a local source of several inflammatory mediators (such as IL-1 beta, IL-6, MCP-1, and TNF-alpha) 
independent of plasma inflammatory biomarkers (16). As stated above, inflammation can induce stiffer 
cardiomyocytes, increased interstitial fibrosis deposition and diastolic dysfunction (41). Moreover, EAT can also 
secrete locally several adipokynes (such as adiponectin, resistin, leptin and others) (16, 46) that can induce 
changes in myocardial structure and function (42). Finally, EAT is a source of free fatty acids (FFA), leading to 
the accumulation of myocardial triglycerides, cardiomyocyte apoptosis, oxidative stress and impaired cardiac 
function(47, 48).  
Epicardial fat has also been reported to correlate with structural changes of the heart such as left atrial enlargement 
(an indirect and chronic marker of diastolic dysfunction), increased LV end-diastolic volume and greater LV mass 
index (24, 26, 49). However, the amount of EAT doesn’t appear to be directly related with cardiac systolic 
dysfunction. We found no significant correlation between EAT and any systolic function parameter, including 
ejection fraction or tissue Doppler derived S’ septal and lateral velocities. 
In summary, because epicardial adipose tissue correlates with the incidence and progression of CAD, with changes 
in myocardial structure and impaired diastolic function it has been proposed that measurement of epicardial fat 
(preferably by CT scan or, alternatively, by echocardiography) can possibly serve as an additional tool for 
cardiovascular risk stratification (42). Although further studies are needed before this can be recommended in 
clinical practice, in a registry of 2751 asymptomatic individuals it has been shown of that adding epicardial fat to 
standard coronary calcium score and Framingham risk score improves specificity and accuracy in predicting major 
adverse cardiovascular events (MACE) (50).  
 
4.3. Study limitations 
This study follows a cross-sectional design, and therefore it does not allow inferring about causality relation 
between adiposity parameters and diastolic dysfunction. Longitudinal studies are now required to further assess 
this association.  
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Also, we have only included patients after myocardial infarction, and therefore we cannot extrapolate these 
conclusions to the general population and other cardiac diseases.  
 
4.4. CONCLUSIONS 
 In this population, impaired diastolic function is associated with increased adiposity parameters, especially 
with visceral and central fat parameters. The association between epicardial fat volume and diastolic dysfunction is 
independent of traditional cardiovascular risk factors and other adiposity parameters. 
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LEGENDS 
Figure A.1. Measurement of epicardial fat volume by computed tomography.  
The level of the axial slices used for pericardial delineation is shown in a coronal projection. EAT was identified 
within the limits of pericardium sac using the adipose tissue attenuation references (-50 to -150 HU). Pericardium 
contour was traced for every 10 mm, starting from the lower visible level of pulmonary artery bifurcation until the 
top level of the pulmonary valve; for every 20 mm from there until the first slice where the diaphragm becomes 
visible; and for every 10mm from this point until the last slice where pericardium is still visible. Final EAT 
volume quantification was calculated as the sum of all slices fat values. 
 
Figure A.2. Scatter plots showing the association between several adiposity parameters and diastolic 
function, assessed by E’ lateral velocity 
r: correlation coefficient between the two variables 
 
Figure A.3. Distribution of epicardial fat volume according to diastolic dysfunction grades.  
* p<0.05 compared to patients with normal diastolic function; 
 † p<0.01 compared to patients with normal diastolic function 
 
 
 
	  
	  
	  
Table	  1	  –	  Characterization	  of	  the	  study	  population	  
Data	  are	  expressed	  as	  mean	  ±	  standard	  deviation	  or	  number	  (percentage).	  AMI,	  acute	  myocardium	  
inflation;	  PCI,	  percutaneous	  Coronary	  Intervention;	  WHO,	  World	  Health	  Organization;	  BMI,	  body	  mass	  
index;	  HDL,	  high-­‐density	  lipoprotein;	  LDL,	  low-­‐density	  lipoprotein;	  NTProBNP,	  N-­‐terminal	  pro-­‐brain	  
natriuretic	  peptide;	  LV,	  left	  ventricle;	  RWT,	  relative	  wall	  thickness;	  LVEF,	  left	  ventricular	  ejection	  
fraction;	  E,	  transmitral	  flow	  velocity	  during	  early	  ventricular	  filling;	  A,	  transmitral	  flow	  velocity	  during	  
atrial	  contraction;	  E’	  lateral,	  tissue	  Doppler	  velocity	  at	  the	  lateral	  wall	  of	  the	  mitral	  annulus	  level	  during	  
early	  ventricular	  filling;	  E’	  septal,	  Tissue	  Doppler	  velocity	  at	  the	  septal	  wall	  of	  the	  mitral	  annulus	  level	  
during	  early	  ventricular	  filling.	  	  
	  	  	  
	  
Clinical	  Data	  
Age,	  years	  
Male	  
Cardiovascular	  Risk	  Factors	  
	  	  	  	  	  Hypertension	  
	  	  	  	  	  Type	  2	  Diabetes	  
	  	  	  	  	  Dyslipidemia	  
	  	  	  	  	  Smoker	  
	  	  	  	  	  Familial	  History	  
AMI	  
	  	  	  	  	  ST-­‐segment	  elevation	  
	  	  	  	  	  Non	  ST-­‐segment	  elevation	  
PCI	  
	  
Anthropometry	  and	  Fat	  distribution	  
	  
	  	  	  	  Overweight	  ,	  WHO	  
	  	  	  	  Obese,	  WHO	  
BMI,	  Kg/m2	  
Weight,	  kg	  
Waist	  perimeter,	  cm	  
Bioimpedance	  fat	  mass,	  %	  
Total	  abdominal	  fat,	  cm2	  
Subcutaneous	  fat,	  cm2	  
Visceral	  fat,	  cm2	  
Epicardial	  fat,	  cm3	  
	  
	  
	  
55,1	  ±	  10.9	  
189	  (84.0%)	  
	  
35	  (15.6%)	  
35	  (15.6%)	  
119	  (52.9%)	  
117	  (52.0%)	  
22	  (9.8%)	  
	  
85	  (37,8%)	  
140	  (62.2%)	  
191	  (84.9%)	  
	  
	  
	  
107	  (47.6%)	  
47	  (20.9%)	  
26.9	  ±	  4.5	  
76.0	  ±	  12.9	  
96.8	  ±	  10.0	  
26.0	  ±	  7.3	  
343.1	  ±	  163.8	  
182.5	  ±	  82.6	  
148.7	  ±	  70.5	  
113.6	  ±	  43.2	  
	  
	  
	  
Analytical	  Data	  
Total	  cholesterol,	  mg/dL	  
HDL,	  mg/dL	  
LDL,	  mg/dL	  
Triglycerides,	  mg/dL	  
Glucose,	  mg/dL	  
Hemoglobin,	  g/L	  
A1c	  hemoglobin,	  %	  
NTProBNP	  
High	  sens.	  C-­‐reative	  protein,	  mg/dL	  
	  	  	  	  
	  
	  
Echocardiography	  
	  	  	  	  	  Septum,	  mm	  
	  	  	  	  	  Posterior	  wall,	  mm	  
	  	  	  	  	  LV	  mass	  index,	  g/m2	  
	  	  	  	  	  RWT,	  unit	  
	  	  	  	  	  Left	  atrium	  volume	  index,	  ml/m2	  
	  	  	  	  	  LV	  end-­‐diastolic	  volume,	  ml/m2	  
	  	  	  	  	  LV	  end-­‐systolic	  volume,	  ml/m2	  
	  	  	  	  	  LVEF,	  %	  
	  	  	  	  	  E	  wave	  velocity,	  cm/s	  
	  	  	  	  	  A	  wave	  velocity,	  cm/s	  
	  	  	  	  	  E/A	  	  
	  	  	  	  	  Deceleration	  time,	  ms	  
	  	  	  	  	  IVRT,	  ms	  
	  	  	  	  	  E’	  lateral	  velocity,	  cm/s	  
	  	  	  	  	  E’	  septal	  velocity,	  cm/s	  
	  	  	  	  	  E/E’	  (mean)	  ratio	  	  
	  	  	  	  	  Diastolic	  dysfunction	  (DD)	  grade	  
	  	  	  	  	  	  	  	  	  	  	  Normal	  	  
	  	  	  	  	  	  	  	  	  	  	  Grade	  1:	  mild	  DD	  
	  	  	  	  	  	  	  	  	  	  	  Grade	  2:	  moderate	  DD	  
	  	  	  	  	  	  	  	  	  	  	  Grade	  3:	  severe	  DD	  	  
	  
	  
137.5	  ±	  32.3	  
39.9	  ±	  10.3	  
75.4	  ±	  35.5	  
123.3	  ±	  56.7	  
97.1	  ±	  18.8	  	  	  	  	  	  
14.1	  ±	  1.4	  
5.9	  ±	  0.9	  
357.0	  ±	  531.0	  
0.35	  ±	  0.70	  
	  
	  
	  
	  
9.6	  ±	  1.6	  
9.3	  ±	  1.5	  
105.3	  ±	  25.0	  
0.35	  ±	  0.07	  
34.8	  ±	  9.3	  
111.3	  ±	  30.6	  
52.4	  ±	  22.4	  
53.6	  ±	  9.3	  
78.1	  ±	  19.4	  
68.1	  ±	  17.6	  
1.22	  ±	  0.50	  
221.8	  ±	  49.8	  
98.7	  ±	  24.4	  
9.8	  ±	  2.3	  
6.9	  ±	  1.8	  
10.4	  ±	  3.9	  
	  
80	  (39.0%)	  
57	  (27.8%)	  
58	  (28.3%)	  
10	  (4.9%)	  
	  
	  
	   E’	  septal	   E’	  lateral	   E/E’	  lateral	   E/E’septal	   E/E’	  mean	  
BMI	   -­‐0.11	  (p=0.11)	  
-­‐0.16	  
(p=0.02)	  
0.21	  
(p=0.001)	  
0.18	  
(p=0.01)	  
0.18	  
(p<0.01)	  
Fat	  mass	  percentage	   -­‐0.26	  (p<0.001)	  
-­‐0.25	  
(p<0.001)	  
0.29	  
(p<0.001)	  
0.31	  
(p<0.001)	  
0.28	  
(p<0.001)	  
Waist	  perimeter/height	   -­‐0.27	  (p<0.001)	  
-­‐0.27	  
(p<0.001)	  
0.28	  
(p<0.001)	  
0.30	  
(p<0.001)	  
0.28	  
(p<0.001)	  
Total	  abdominal	  fat	   -­‐0.19	  (p<0.01)	  
-­‐0.20	  
(p<0.01)	  
0.26	  
(p<0.001)	  
0.23	  
(p=0.001)	  
0.22	  
(p<0.01)	  
Subcutaneous	  abdominal	  fat	   -­‐0.10	  (p=0.15)	  
-­‐0.09	  
(p=0.20)	  
0.20	  
(p<0.01)	  
0.20	  
(p<0.01)	  
0.17	  
(p=0.02)	  
Visceral	  abdominal	  fat	   -­‐0.23	  (p=0.001)	  
-­‐0.27	  
(p<0.001)	  
0.25	  
(p<0.001)	  
0.21	  
(p<0.01)	  
0.21	  
(p<0.01)	  
Epicardial	  fat	   -­‐0.26	  (p<0.001)	  
-­‐0.28	  
(p<0.001)	  
0.28	  
(p<0.001)	  
0.24	  
(p<0.001)	  
0.25	  
(p<0.001)	  
	   	   	   	   	   	  
Table	  2	  -­‐	  Correlation	  coefficients	  between	  several	  adiposity	  parameters	  and	  diastolic	  function.	  	  
	   1	  
Table	  3	  –	  Univariate	  and	  multivariate	  linear	  regression	  analyses	  for	  the	  association	  of	  diastolic	  function	  parameters	  (E’	  velocity	  and	  E/E’	  ratio)	  with	  adiposity	  parameters.	  	  
*Adjusted	  for	  age,	  hypertension	  history,	  sex.	  	  
β,	  regression	  coefficient.	  95%CI,	  95%	  confidence	  interval	  
	  
	  
	   E’	  septal	  velocity	  
	   	  
E’	  lateral	  
velocity	  
	   	  
E/E’	  ratio	  
	   Crude	  β	  (95%	  CI)	  
Adjusted	  β*	  
(95%	  CI*)	   p	  value*	  
	  
Crude	  β	  
(95%	  CI)	  
Adjusted	  β*	  
(95%	  CI*)	   p	  value*	  
	  
Crude	  β	  
(95%	  CI)	  
Adjusted	  β*	  
(95%	  CI*)	   p	  value*	  
Weight	   	   	   	   	   	   	   	   	   	   	   	  	  
BMI	   -­‐0.05	  (-­‐0.10	  to	  0.00)	  
-­‐0.05	  
(-­‐0.09	  to	  -­‐0.01)	   0.02	  
	   -­‐0.08	  
(-­‐0.16	  to	  -­‐0,01)	  	  
-­‐0.09	  
(-­‐0.16	  to	  -­‐0,02)	   <0.01	  
	   0.09	  
(-­‐0,03	  to	  0.20)	  
0.10	  
(-­‐0.01	  to	  0.22)	   0.08	  
Fat	  mass	  %	   -­‐0.06	  (-­‐0.09	  to	  -­‐0.03)	  
-­‐0.04	  
(-­‐0.07	  to	  0.00)	   0.04	  
	   -­‐0.09	  
(-­‐0.14	  to	  -­‐0.04)	  	  
-­‐0.08	  
(-­‐0.13	  to	  -­‐0.02)	   <0.01	  
	   0.09	  
(0.01	  to	  0.16)	  
0.08	  
(-­‐0.02	  to	  0.17)	   0.11	  
WP/height	   -­‐0.09	  (-­‐0.13	  to	  -­‐0.05)	  
-­‐0.05	  
(-­‐0.09	  to	  -­‐0.01)	   0.02	  
	   -­‐0,13	  
(-­‐0.19	  to	  -­‐0.07)	  	  
-­‐0,09	  
(-­‐0.15	  to	  -­‐0.03)	   <0.01	  
	   0.11	  
(0.02	  to	  0.21)	  
0.09	  
(-­‐0.01	  to	  0.19)	   0.07	  
Total	  abdominal	  
Fat	  (x10)	  
-­‐0.03	  
(-­‐0.05	  to	  -­‐0.01)	  
0.02	  
(-­‐0.04	  to	  0.00)	   0.07	  
	   -­‐0.05	  
(-­‐0.07	  to	  -­‐0.02)	  	  
-­‐0.03	  
(-­‐0.06	  to	  0.00)	   0.03	  
	   0.04	  
(0.00	  to	  0.09)	  
0.04	  
(-­‐0.01	  to	  0.08)	   0.09	  
Subcutaneous	  
abdominal	  fat	  (x10)	  
-­‐0.02	  
(-­‐0.05	  to	  0.01)	  
-­‐0.02	  
(-­‐0.05	  to	  0.00)	   0.23	  
	   -­‐0.03	  
(-­‐0,08	  to	  0.01)	  	  
-­‐0.04	  
(-­‐0.08	  to	  0.00)	   0.07	  
	   0.04	  
(-­‐0.03	  to	  0.11)	  
0.04	  
(-­‐0.03	  to	  0.11)	   0.25	  
Visceral	  abdominal	  fat	  
(x10)	  
-­‐0.06	  
(-­‐0.09	  to	  -­‐0.03)	  
-­‐0.03	  
(-­‐0.06	  to	  0.01)	   0.15	  
	   -­‐0.10	  
(-­‐0.15	  to	  -­‐0.05)	  	  
-­‐0.05	  
(-­‐0.10	  to	  0.00)	   0.04	  
	   0.08	  
(0.001to	  0.16)	  
0.08	  
(0.00	  to	  0.16)	   0.06	  
Epicardial	  fat	  (x10)	   -­‐0.11	  (-­‐0.17	  to	  -­‐0.06)	  
-­‐0.06	  
(-­‐0.12	  to	  -­‐0.01)	   0.02	  
	   -­‐0.17	  
(-­‐0.25	  to	  -­‐0.09)	  
-­‐0.11	  
(-­‐0.19	  to	  -­‐0.03)	   <0.01	  
	   0.19	  
(0.07	  to	  0.31)	  
0.19	  
(0.06	  to	  0.32)	   <0.01	  
	  	  	  
Normal	  
Diastolic	  
function	  	  
(n=80)	  
Grade	  1	  
DD	  	  
(n=	  57)	  
Grade	  2	  
DD	  	  
(n=	  58)	  
Grade	  3	  
DD	  	  
(n=	  10)	  
p	  value	  
(for	  trend)	  
BMI	   	  25.8	  ±	  4.23	   26.9	  ±	  5.6	   	  26.8	  ±	  3.7*	   	  25.7	  ±	  10.9	   0.17	  
Fat	  mass	  %	   	  22.1	  ±	  7.9	   25.5	  ±	  11.7†	   	  25.9	  ±	  9.2†	   24.8	  ±	  16.1	   <0.01	  
Waist	  perimeter/height	   	  55.4	  ±	  7.0	   58.3.0	  ±	  7.1†	   58.5	  ±	  7.9†	   56.2	  ±	  15.4	   	  <0.01	  
Total	  abdominal	  
fat	   	  270.0	  ±	  151.6	   331.1	  ±	  149.3
*	   	  321.0	  ±	  170.5†	   	  308.8	  ±300.6	   	  0.02	  
Subcutaneous	  abdominal	  
fat	   	  155.32	  ±	  90.5	   165.4	  ±	  99.6	   175.3	  ±74.7	   194.4	  ±	  135.9	   	  0.13	  
Visceral	  abdominal	  fat	   	  111.6	  ±	  103.7	   141.0	  ±	  75.9
†
	  
160.0	  ±	  88.8†	   134.0	  ±	  155.6	   	  0.01	  
Epicardial	  fat	   93.0	  ±	  52.3	   111.15	  ±	  60.2*	   117.15	  ±	  64.3†	   136.4	  ±	  83.1†	   	  0.001	  
	  	   	  	   	  	   	  	   	  	   	  	  
	  Table	  4	  –	  Distribution	  of	  adiposity	  parameters	  according	  to	  diastolic	  function	  grades.	  
Data	  expressed	  as	  median	  ±	  interquartile	  range;	  
*	  p<0.05	  compared	  to	  patients	  with	  normal	  diastolic	  function;	  	  
†	  p<0.01	  compared	  to	  patients	  with	  normal	  diastolic	  function	  
	  
	  
	  	  
	  	  
Figure	  A.1.	  Measurement	  of	  epicardial	  fat	  volume	  by	  computed	  tomography.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	   	   	   Figure	  A.2.	  Scatter	  plots	  showing	  the	  association	  between	  several	  adiposity	  parameters	  and	  diastolic	  function,	  assessed	  by	  E’	  lateral	  velocity	  
	  	  
Figure	  A.3.	  Distribution	  of	  epicardial	  fat	  volume	  according	  to	  diastolic	  dysfunction	  grades.	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references should be compiled at the end of the article in the Vancouver style, except that ALL authors 
should be listed.  
 
Complete information should be given for each Reference including the title of the article, abbreviated 
journal title and page numbers.  
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the reputation of those involved in it.  
 
Experiments involving animals should be appropriately designed, correctly analysed and then 
transparently reported, to both increase the validity of the results, and maximise the scientific gain. A 
minimum amount of relevant information must be included in manuscripts published in this journal to 
ensure that the methods and results of a study can be reviewed, analysed and repeated. EJHF will 
therefore refer to the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines as 
the basis for the process of reviewing manuscripts of research involving animals.  
 
These guidelines were generated by The National Centre for the Replacement, Refinement and 
Reduction of Animals in Research, which is an independent scientific organisation, established by the 
UK Government, in consultation with scientists, statisticians, journal editors and research funders. 
Author contribution form 
All authors and contributors should submit an author contribution form/statement (download here) 
specifying their particular role in the study/article. The European Journal of Heart Failure will ask for 
signed copies of these forms at a date after submission. Articles will not be published until signed 
contribution forms from all authors have been received. Completed forms should be sent by email or 
faxed (+44 1482 461779) to the editorial office. 
Open access option for authors 
European Journal of Heart Failure authors have the option to publish their paper under the Oxford 
Open initiative; whereby, for a charge, their paper will be made freely available online immediately 
upon publication. After your manuscript is accepted the corresponding author will be required to accept 
a mandatory licence to publish agreement. As part of the licensing process you will be asked to indicate 
whether or not you wish to pay for open access. If you do not select the open access option, your paper 
will be published with standard subscription-based access and you will not be charged. 
You can pay Open Access charges using our Author Services site. This will enable you to pay online 
with a credit/debit card, or request an invoice by email or post. Open access charges are 
£1700/$3000/€2550; discounted rates are available for authors based in some developing countries 
(click here for a list of qualifying countries). Please note that these charges are in addition to any colour 
charges that may apply.  
 
Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the 
European Union, OUP will assume that the service is provided for business purposes. Please provide a 
VAT number for yourself or your institution and ensure you account for your own local VAT correctly. 
Self-archiving and post-print policy 
Authors may deposit the post-print of their article into PubMedCentral, other subject repositories or 
institutional repositories, but must stipulate that public availability be delayed until 12 months after the 
first online publication. For further details of this policy please visit: Author Self-archiving Policy 
Copyright information 
It is a condition of publication in the Journal that authors grant an exclusive licence to The European 
Society of Cardiology. This ensures that requests from third parties to reproduce articles are handled 
efficiently and consistently and will also allow the article to be as widely disseminated as possible. As 
part of the licence agreement, authors may use their own material in other publications provided that 
the Journal is acknowledged as the original place of publication and Oxford University Press is notified 
in writing and in advance.  
 
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online 
copyright licence to publish form.  
 
Please note that by submitting an article for publication you confirm that you are the 
corresponding/submitting author and that Oxford University Press ("OUP") may retain your email 
address for the purpose of communicating with you about the article. You agree to notify OUP 
immediately if your details change. If your article is accepted for publication OUP will contact you 
using the email address you have used in the registration process. Please note that OUP does not retain 
copies of rejected articles. 
Permissions information 
If illustrations or figures are to be duplicated from previously published work, written permission must 
be obtained both from the publisher and the author, and a credit line giving the source added to the 
relevant Figure Legend. If text material (250 to 300 words) is to be reproduced from published sources, 
written permission is required from both publisher and author. For shorter quotations, it is sufficient to 
add a bibliographic credit. The Letters containing the permission for the reproduction of either text or 
illustrations must accompany the manuscript. If you have been unable to obtain permission, please 
indicate this.  
 
If no permissions are required, submit a Word document with your figure stating this, please. 
Proofs 
Page proofs will be sent to the corresponding author. Please provide an e-mail address to enable page 
proofs to be sent as PDF files via e-mail. These should be checked thoroughly for any possible changes 
or typographic errors. Significant alterations instigated at this stage by the author will be charged to the 
author.  
 
It is the intention of the Editor to review, correct and publish your article as quickly possible. To 
achieve this it is important that all of your corrections are returned to us in one all-inclusive mail or fax. 
Subsequent additional corrections will not be possible, so please ensure that your first communication 
is complete. 
Online access and offprints 
Details of free online access will be sent to the corresponding author, who may then circulate them to 
co-authors. If the purchase of offprints is required, these can be ordered using the Oxford Journals 
Author Services site when your paper enters production. Late orders submitted after the journal is in 
press are subject to increased prices.  
 
Orders from the UK will be subject to the current UK VAT charge. For orders from elsewhere in the 
EU you or your institution should account for VAT by way of a reverse charge. Please provide us with 
your or your institution’s VAT number. 
Language editing 
Particularly if English is not your first language, before submitting your manuscript you may wish to 
have it edited for language. This is not a mandatory step, but may help to ensure that the academic 
content of your paper is fully understood by journal editors and reviewers. Language editing does not 
guarantee that your manuscript will be accepted for publication. If you would like information about 
such services please clickhere. There are other specialist language editing companies that offer similar 
services and you can also use any of these. Authors are liable for all costs associated with such 
services. 
 



